Recently, the result of a phase II clinical trial showed that an innovative anti-PD-1 antibody geptanolimab (GB226) has showed potent activity in r/r PTCL, which may provide new treatment approach for r/r PTCL patients [30]. Here, PDCD1 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.